Document Detail


Clinical responses to oxprenolol in the elderly.
MedLine Citation:
PMID:  6356866     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Data from 6 controlled clinical trials of oxprenolol carried out in the United States were reviewed to determine the efficacy and tolerability of oxprenolol in patients aged greater than or equal to 55 years. All study designs but 1 called for dosage to be increased to a maximum of 480 mg/day. In a 10-week trial of oxprenolol versus placebo given twice daily, oxprenolol reduced diastolic pressure by 8 mm Hg, while placebo reduced it by 3 mm Hg. A comparison of once-daily with twice-daily dosing showed similar results for both groups: -12/-6 mm Hg for once-daily and -9/-8 mm Hg for twice-daily. There were 2 short-term studies comparing oxprenolol and placebo, both given in addition to hydrochlorothiazide. In the first, the change in blood pressure with oxprenolol was -18/-14 mm Hg and with placebo was +6/-3 mm Hg; only 3 of 14 patients receiving oxprenolol received a maximal dosage. In the follow-up study, most of the dosages were titrated to maximum; reductions were -9/-9 mm Hg with oxprenolol treatment and 0/-12 mm Hg with placebo. Two long-term studies compared oxprenolol and propranolol, also as combination therapy with hydrochlorothiazide. In the 14-week study, the reduction in blood pressure was slightly better with oxprenolol: -15/-15 versus -12/-11 mm Hg. In the 27-week study, almost half of the patients in the oxprenolol group received the maximal dosage. Blood pressure was reduced 2 or 3 mm Hg less with oxprenolol than with propranolol. Oxprenolol was well tolerated in the elderly; it produced a low incidence of typical beta-blocker side effects even when given in a once-daily regimen.
Authors:
R A Ellis
Related Documents :
8179846 - Antihypertensive effects of aerobic exercise. a brief meta-analytic review of randomize...
20626346 - Why and how we should treat elderly patients with hypertension?
15364316 - Stroke prevention with the angiotensin ii type 1-receptor blocker candesartan in elderl...
23456876 - Using plethysmography to determine erythropoietin's impact on neural control of ventila...
7527106 - Comparison of the efficacy and safety of trandolapril and captopril for 16 weeks in mil...
7049926 - Epidemiology and genetics of hypertension.
Publication Detail:
Type:  Clinical Trial; Comparative Study; Journal Article    
Journal Detail:
Title:  The American journal of cardiology     Volume:  52     ISSN:  0002-9149     ISO Abbreviation:  Am. J. Cardiol.     Publication Date:  1983 Nov 
Date Detail:
Created Date:  1983-12-17     Completed Date:  1983-12-17     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  0207277     Medline TA:  Am J Cardiol     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  62D-65D     Citation Subset:  AIM; IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aged
Aging / drug effects*
Clinical Trials as Topic
Drug Therapy, Combination
Drug Tolerance
Humans
Hydrochlorothiazide / administration & dosage
Hypertension / drug therapy
Middle Aged
Oxprenolol / administration & dosage,  adverse effects,  therapeutic use*
Placebos
Chemical
Reg. No./Substance:
0/Placebos; 58-93-5/Hydrochlorothiazide; 6452-71-7/Oxprenolol

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  United States experience with oxprenolol in hypertension.
Next Document:  Immunocytochemical localization of glucagonlike and gastric inhibitory polypeptidelike peptides in t...